当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Verquvo
申请企业
MERCK SHARP AND DOHME CORP
承诺描述
A study in juvenile rats to evaluate the effects of vericiguat on cranial, appendicular, and axial bone development to support dosing in humans =28 days of age
承诺状态描述
Per FDA letter dated 02/26/2021, this PMR has been released.